Specific expression of endoglin (CD105) in endothelial cells of intratumoral blood and lymphatic vessels in pancreatic cancer

Pancreas

Volumn 37, Issue 3, 2008, Pages 275-281

  Yoshitomi, Hideyuki ^a   Kobayashi, Souichi ^a   Ohtsuka, Masayuki ^a   Kimura, Fumio ^a   Shimizu, Hiroaki ^a   Yoshidome, Hiroyuki ^a   Miyazaki, Masaru ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Endoglin (CD105); Endothelial cell; Lymphangiogenesis; Pancreatic cancer

Indexed keywords

ANTIBODY; ENDOGLIN; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL; MALE; MICROVASCULATURE; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; AGED; CAPILLARY; DISEASE FREE SURVIVAL; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPH VESSEL ENDOTHELIUM; MIDDLE AGED; MORTALITY; PANCREAS CARCINOMA; PANCREAS TUMOR; TIME; VASCULAR ENDOTHELIUM; VASCULARIZATION;

AGED; ANTIGENS, CD; CAPILLARIES; CARCINOMA, PANCREATIC DUCTAL; DISEASE-FREE SURVIVAL; ENDOTHELIUM, LYMPHATIC; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEPTORS, CELL SURFACE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 58149330686     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/mpa.0b013e3181690b97     Document Type: Article

References (35)

1. Fennelly D, Kelsen DP. The role of chemotherapy in the treatment of adenocarcinoma of the pancreas. Hepatogastroenterology. 1996;43: 356-362.
2. Yamanaka Y, Friess H, Buchler M, et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res. 1993;53:5289-5296.
3. Itakura J, Ishikawa T, Friess H, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res. 1997;3:1309-1316.
4. Ikeda N, Adachi M, Taki T, et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer. 1999;79:1553-1563.
5. Seo Y, Baba H, Fukuda T, et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 2000; 88:2239-2245.
6. Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res. 2002; 62:1996-2003.
7. Bockhorn M, Tsuzuki Y, Xu L, et al. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin Cancer Res. 2003;9:4221-4226.
8. Buchler P, Reber HA, Ullrich A, et al. Pancreatic cancer growth is inhibited by blockade of VEGF-RII. Surgery. 2003;134:772-782.
9. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23:8033-8040.
10. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
11. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279: 377-380.
12. Cheifetz S, Bellon T, Cales C, et al. Endoglin is a component of the transforming growth factor-b receptor system in human endothelial cells. J Biol Chem. 1992;267:19027-19030.
13. Lebrin F, Goumans MJ, Jonker L, et al. Endoglin promotes endothelial cell proliferation and TGF-b/ALK1 signal transduction. EMBO J. 2004;23:4018-4028.
14. Li DY, Sorensen LK, Brooke BS, et al. Defective angiogenesis in mice lacking endoglin. Science. 1999;284:1534-1537.
15. Wang JM, Kumar S, Pye D, et al. A monoclonal antibody detects heterogeneity in vascular endothelium of tumors and normal tissues. Int J Cancer. 1993;54:363-370.
16. Akagi K, Ikeda Y, Sumiyoshi Y, et al. Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development. Surgery. 2002;131:S109-S113.
17. Ho JW, Poon RT, Sun CK, et al. Clinicopathological and prognostic implications of endoglin (CD105) expression in hepatocellular carcinoma and its adjacent non-tumorous liver. World J Gastroenterol. 2005; 11:176-181.
18. Yao Y, Kubota T, Takeuchi H, et al. Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology. 2005;25:201-206.
19. Fonsatti E, Altomonte M, Nicotra MR, et al. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene. 2003;22:6557-6563.
20. Tan GH, Wei YQ, Tian L, et al. Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen. Eur J Immunol. 2004;34:2012-2021.
21. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
22. Vecchi A, Garlanda C, Lampugnani MG, et al. Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. Eur J Cell Biol. 1994;63:247-254.
23. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol. 2002;15:434-440.
24. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004;363: 1049-1057.
25. Hirakawa S, Hong Y, Harvey N, et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol. 2003;162: 575-586.
26. Salven P, Mustjoki S, Alitalo R, et al. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood. 2003;101:168-172.
27. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature. 2005;438:946-953.
28. Achen MG, Mann GB, Stacker SA. Targeting lymphangiogenesis to prevent tumor metastasis. Br J Cancer. 2006;94:1355-1360.
29. Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-b superfamily. J Biol Chem. 1999;274:584-594.
30. Li C, Hampson IN, Hampson L, et al. CD105 antagonizes the inhibitory signaling of transforming growth factor b1 on human vascular endothelial cells. FASEB J. 1999;14:55-64.
31. Seon BK, Matsuno F, Haruta Y, et al. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelia cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res. 1997;3:1031-1044.
32. Matsuno F, Haruta Y, Kondo M, et al. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res. 1999;5:371-382.
33. Tabata M, Kondo M, Haruta Y, et al. Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using 125I-labeled anti-endoglin monoclonal antibodies. Int J Cancer. 1999;82:737-742.
34. Takahashi N, Haba A, Matsuno F, et al. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res. 2001;61:7846-7854.
35. Tsujie M, Uneda S, Tsai H, et al. Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: Differenced in growth rate and therapeutic response between tumors growing at different sites. Int J Oncol. 2006;29:1087-1094.